Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10637/15056

A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP‑DC) or with tumor lysate (OC‑DC) in patients with advanced high‑grade ovarian serous carcinoma


Vista previa

Ver/Abrir:
 Phase_Sarivalasis_et_al_JTranslMed_2019.pdf
  Acceso restringido
919,01 kB
Adobe PDF
 Request a copy
Título : A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP‑DC) or with tumor lysate (OC‑DC) in patients with advanced high‑grade ovarian serous carcinoma
Autor : Sarivalasis, Apostolos
Boudousquié, Caroline
Balint, Klara
Stevenson, Brian J.
Gannon, Philippe O.
Ianco, Emanuela Marina
Rossier, Laetitia
Martín Lluesma, Silvia
Mathevet, Patrice
Semphoux, Christine
Coukos, George
Dafni, Urari
Harari, Alexandre
Bassani Sternberg, Michal
Kandalaft, Lana E.
Materias: Ovarian cancerDendritic cell vaccineNeoantigenNeoepitopeCancer immunotherapyCyclophosphamide
Editorial : BMC
Resumen : Background: Most ovarian cancer patients are diagnosed at a late stage with 85% of them relapsing after surgery and standard chemotherapy; for this reason, new treatments are urgently needed. Ovarian cancer has become a candidate for immunotherapy by reason of their expression of shared tumor-associated antigens (TAAs) and private mutated neoantigens (NeoAgs) and the recognition of the tumor by the immune system. Additionally, the presence of intraepithelial tumor infiltrating lymphocytes (TILs) is associated with improved progression-free and overall survival of patients with ovarian cancer. The aim of active immunotherapy, including vaccination, is to generate a new anti-tumor response and amplify an existing immune response. Recently developed NeoAgs-based cancer vaccines have the advantage of being more tumor specific, reducing the potential for immunological tolerance, and inducing robust immunogenicity. Methods: We propose a randomized phase I/II study in patients with advanced ovarian cancer to compare the immunogenicity and to assess safety and feasibility of two personalized DC vaccines. After standard of care surgery and chemotherapy, patients will receive either a novel vaccine consisting of autologous DCs pulsed with up to ten peptides (PEP-DC), selected using an agnostic, yet personalized, epitope discovery algorithm, or a sequential combination of a DC vaccine loaded with autologous oxidized tumor lysate (OC-DC) prior to an equivalent PEP-DC vaccine. All vaccines will be administered in combination with low-dose cyclophosphamide. This study is the first attempt to compare the two approaches and to use NeoAgs-based vaccines in ovarian cancer in the adjuvant setting. Discussion: The proposed treatment takes advantage of the beneficial effects of pre-treatment with OC-DC prior to PEP-DC vaccination, prompting immune response induction against a wide range of patient-specific antigens, and amplification of pre-existing NeoAgs-specific T cell clones. Trial registration This trial is already approved by Swissmedic (Ref.: 2019TpP1004) and will be registered at http://www. clini caltr ials.gov before enrollment opens.
URI : http://hdl.handle.net/10637/15056
Derechos: http://creativecommons.org/licenses/by-nc-sa/4.0/deed.es
ISSN : 1479-5876
Fecha de publicación : 26-nov-2019
Centro : Universidad San Pablo-CEU
Aparece en las colecciones: Medicina





Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.